Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 11/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2127338 | 0.92 | EGFR (0.49) | EGFRERBB2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2127400 | 0.92 | ALDH1A1 (0.47) | EGFRERBB2CSNK2A1DYRK1ADYRK1B | |
| SCHEMBL2126389 | 0.91 | ALDH1A1 (0.47) | EGFRERBB2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2123440 | 0.89 | CSNK2A1 (0.52) | EGFRERBB2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL18686178 | 0.88 | CSNK2A1 (0.44) | EGFRERBB2CSNK2A1ALDH1A1 | |
| SCHEMBL2124067 | 0.88 | MAPT (0.44) | EGFRERBB2CSNK2A1ALDH1A1 | |
| SCHEMBL2122519 | 0.84 | CSNK2A1 (0.48) | EGFRERBB2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2124785 | 0.84 | BRAF (0.46) | EGFRERBB2CSNK2A1FYNALDH1A1 | |
| SCHEMBL2125452 | 0.83 | CSNK2A1 (0.47) | EGFRERBB2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL2125777 | 0.82 | CSNK2A1 (0.46) | EGFRERBB2CSNK2A1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | claimed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | claimed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | claimed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | claimed |
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2443123-B1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-06 | — | — | US | disclosed |
| US-8377945-B2 | Small molecule inhibitors of spleen tyrosine kinase (SYK) | RIGEL PHARMACEUTICALS INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2443123-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | Rigel Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147898-A2 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | RIGEL PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | MIDCAP FINANCIAL TRUST | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216955-A1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | HLA-DRB1, CD74, CHI3L1 | EGFR 4464/4885ERBB2 4830/4885CSNK2A1 4410/4885 |
| US-20100316649-A1 | SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) | SYK, BTK, LCK | EGFR 1784/4885ERBB2 471/4885CSNK2A1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.